Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Bacillus Calmette-Guerin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections: A review of immunological aspects, clinical effects and BCG infections

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. APMIS pandemic editorial

    Research output: Contribution to journalEditorialResearchpeer-review

  2. Pandemics: past, present, future: That is like choosing between cholera and plague

    Research output: Contribution to journalReviewResearchpeer-review

  3. Beta-hemolytic streptococci A, C and G are susceptible to cloxacillin

    Research output: Contribution to journalLetterResearchpeer-review

  4. The discovery of bacterial biofilm in patients with muscle invasive bladder cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Morbidity and Days Alive and Out of Hospital Within 90 Days Following Radical Cystectomy for Bladder Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Short-term morbidity and mortality following radical cystectomy: a systematic review

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Familial resemblance in markers of testicular function in fathers and their young sons: a cross-sectional study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Surgical Management of Muscle Invasive Bladder Cancer: A Review of Current Recommendations

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Bacillus Calmette–Guérin (BCG) immunotherapy for bladder cancer has been used since 1976 when the first evidence of its ability to lower recurrence and progression rates was published. Today, BCG immunotherapy is the choice of care for high-grade non-muscle invasive bladder cancer (NMIBC) after transurethral resection. This article presents indications and procedure of BCG instillations, and outlines the effects on recurrence and progression of NMIBC. The BCG-induced immunity in NMIBC is not yet fully understood. Animal studies point towards BCG inducing specific tumour immunity. We describe the current knowledge of how this immunity is induced, from internalization of BCG bacilli in urothelial cells, to cytokine- and chemokine-mediated recruitment of neutrophils, monocytes, macrophages, T cells, B cells and natural killer cells. In addition, we describe the process of trained immunity, the non-specific protective effects of BCG. Recent studies also indicate that dysbiosis of the urinary microbiome may cause lower urinary tract dysfunction. Side effects of BCG bladder instillations range from common, mild and transient symptoms, such as dysuria and flu-like symptoms, to more severe and rarely occurring life-threatening complications. We review the literature and give an overview of reported incidences and management of BCG infections after intravesical instillation.

Original languageEnglish
JournalAPMIS - Journal of Pathology, Microbiology and Immunology
Volume128
Issue number2
Pages (from-to)92-103
Number of pages12
ISSN0903-4641
DOIs
Publication statusPublished - Feb 2020

    Research areas

  • BCG, BCG infection, bladder cancer, immunotherapy, intravesical instillation

ID: 58623032